Copenhagen, Denmark, July 13, 2026. Bavarian Nordic A/S (OMX: BAVA) has completed the share buy-back program launched on June 2, 2026, after repurchasing shares with a total value of approximately DKK 150 million.
The completed program represented the third and final portion of Bavarian Nordic’s planned share repurchases of up to DKK 500 million during 2026. The company intends to retain the acquired shares as treasury stock as part of its ongoing capital structure management.
The share repurchases were carried out in compliance with Regulation (EU) No. 596/2014 on market abuse and Commission Delegated Regulation (EU) 2016/1052. Together, these regulations establish the applicable Safe Harbour framework for share repurchase transactions.
Share Repurchase Activity
Bavarian Nordic purchased a total of 820,607 shares during the program. Nordea conducted the transactions on behalf of the company.
The repurchases completed since the previous transaction announcement on July 6, 2026, were as follows:
| Transaction period | Number of shares | Average purchase price | Transaction value |
| Accumulated through July 6, 2026 | 664,764 | DKK 181.28 | DKK 120,511,072 |
| July 6, 2026 | 53,566 | DKK 190.23 | DKK 10,190,032 |
| July 7, 2026 | 52,002 | DKK 188.94 | DKK 9,825,367 |
| July 8, 2026 | 4,725 | DKK 186.45 | DKK 880,984 |
| July 9, 2026 | 45,550 | DKK 188.62 | DKK 8,591,609 |
| Total under the program | 820,607 | DKK 182.79 | DKK 149,999,064 |
Information covering each individual transaction completed under the program is available through Bavarian Nordic’s official website.
Following the completion of the buy-back, Bavarian Nordic holds 3,558,591 treasury shares. These shares represent approximately 4.49% of the company’s total share capital.
About Bavarian Nordic
Bavarian Nordic is a global vaccine company focused on developing and supplying innovative vaccines that support public health and disease prevention. The company is a major supplier of mpox and smallpox vaccines to governments and public health authorities and maintains a portfolio of vaccines for travel-related diseases.
Additional company information is available at the Bavarian Nordic corporate website.
Forward-Looking Statements
This press release may contain forward-looking statements relating to Bavarian Nordic’s objectives, plans, future activities, performance and anticipated developments. Such statements involve risks, uncertainties and other factors that may cause actual outcomes to differ materially from those expressed or implied.
Forward-looking statements are not guarantees of future performance and are subject to circumstances that may be outside the company’s control. Bavarian Nordic assumes no obligation to update or revise these statements following publication, except where required by applicable law.
Investor Contacts
Europe
Anders Hjort
Head of Investor Relations
Email: [email protected]
Telephone: +45 33 26 83 83
United States
Graham Morrell
Gilmartin Group
Email: [email protected]
Telephone: +1 781 686 9600
Media Contact
Nicole Seroff
Vice President, Corporate Affairs
Email: [email protected]
Telephone: +45 53 88 06 03